Nat. Immunol. 10, 958–964 (2009); published online 16 August 2009; corrected after print 18 September 2009
In the version of this article initially published, two citations were not included. These citations, together with text describing their content, have been added to page 958, column 2, as follows: “As neuronal loss is thought to contribute to the pathogenesis of progressive multiple sclerosis5, and as PARP-1 inhibitors suppress the incidence and severity of experimental autoimmune encephalomyelitis (EAE)36,37, we investigated the function of 15-oxysterols in multiple sclerosis and EAE.” The added references are as follows:
The error has been corrected in the HTML and PDF versions of the article.
References
Scott, G.S. et al. Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis. J. Neuroimmunol. 117, 78–86 (2001).
Scott, G.S. et al. The therapeutic effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J. Pharmacol. Exp. Ther. 310, 1053–1061 (2004).
Additional information
The online version of the original article can be found at 10.1038/ni.1775
Rights and permissions
About this article
Cite this article
Farez, M., Quintana, F., Gandhi, R. et al. Correction: Corrigendum: Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 11, 97 (2010). https://doi.org/10.1038/ni0110-97c
Issue Date:
DOI: https://doi.org/10.1038/ni0110-97c
This article is cited by
-
Mycobacteria-Induced Suppression of Autoimmunity in the Central Nervous System
Journal of Neuroimmune Pharmacology (2010)
